Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing
substances to them without harming normal cells. Colony-stimulating factors such as
sargramostim may increase the number of immune cells found in bone marrow or peripheral
blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor
cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with
sargramostim and interleukin-2 in treating children with neuroblastoma who have just
completed bone marrow or peripheral stem cell transplantation